Tibulizumab clinical trials

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

This study is testing a new medicine, tibulizumab, for an illness called systemic sclerosis (scleroderma). We want to see if it helps improve symptoms over 24 weeks, followed by an additional 28 weeks where everyone gets the study drug.